Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
about
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerA placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer.The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trialsSmall molecule TSHR agonists and antagonists.Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases.Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone AdministrationEconomic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective.The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties.In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis.Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer.Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy.Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer.Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre.Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma.Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated ThyroglobuliIndirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study.Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.Guidelines for the management of thyroid cancer
P2860
Q30367068-DC8473F4-BEEF-4662-8752-4B3D0B447A6EQ33597636-7EA257AA-3CEB-4D70-9110-C14854E45DFBQ33749205-BEACC747-C654-4644-8380-67873769D12FQ33879256-C0C5DA8A-0A75-447F-869E-269917E81575Q34625366-EBB6C0F4-1EFB-4297-BE8C-80BD85E2A87FQ35029676-D0198255-DC9A-4EC6-948D-20C1901A49B8Q35201397-45C84CC6-9703-4194-87FB-97A9142A873EQ36240455-0C3D529D-D358-4478-829A-8D2521E9653DQ36241223-55888F46-A6F4-47B5-90A7-6BA460490288Q36489166-AB2BA0F7-561C-4218-B97C-481190A471BBQ36666417-171B3BA5-3977-426E-B14D-7AC9CCC7B1DDQ36948480-CBE810A4-9452-482F-B419-7567694C553AQ37127629-0D086248-D175-464F-AFB1-8E7F60C24A7CQ37573792-3688847C-DF45-464D-BBE3-5056CE9A2B14Q38063535-A9D36E3F-7F93-4368-A308-4EDB0FD57CB2Q38716870-CC0A24E1-73AE-466D-B465-A782DCE1944BQ39607701-E4A1E1B2-B681-479C-B748-5DFE0C719E17Q42094673-A5A73F38-934B-491F-83EB-F933AB2F3388Q42427139-71EAFB65-342D-4ABE-B7ED-71C47E1AD481Q42478263-0ACC16FE-6AAD-42EA-AB71-6AE083CAF32FQ44295223-DA42C751-3AAA-41DD-ABE0-00D8A2402254Q48074912-624A67DD-3980-4795-AF46-5165FB63BFE5Q48096442-902E3F84-77D1-4C9D-A0D9-8C65EE7B3762Q50341379-86EED8CF-0098-4438-993A-8E6532A54A41Q53198789-176001E0-80D3-4816-8FB1-733C5F182083Q55076373-C0D74855-24C4-4E61-82FD-E2240A02E984Q56554243-600F3C01-D3F3-4B87-BDCD-99C4D184629E
P2860
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@en
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@nl
type
label
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@en
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@nl
prefLabel
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@en
Quality of life and effectiven ...... ferentiated thyroid carcinoma.
@nl
P2093
P356
P1433
P1476
Quality of life and effectiven ...... fferentiated thyroid carcinoma
@en
P2093
Cheong Soo Park
Euy-Young Soh
Jandee Lee
Woong Youn Chung
P304
P356
10.1089/THY.2009.0187
P577
2010-02-01T00:00:00Z